mRNA pioneers refocus on therapeutics
Flush with COVID-19 vaccine success, pharma and biotech companies are moving forward with mRNAs engineered to make therapeutic proteins.
When the COVID-19 pandemic erupted in early 2020, messenger RNAs (mRNAs) designed to produce therapeutic proteins were moving towards clinical trials. Companies in the field — including Moderna, BioNTech, CureVac, Arcturus and Translate Bio—all pivoted to vaccines. Now that the success of the Moderna and BioNTech/Pfizer COVID-19 vaccines has validated the mRNA technology platform, they’re doubling down on the goal of converting human cells into protein factories to treat disease. “The wind is at our backs now, and we must use that newfound momentum to change the outcome for other diseases, too,” says John Androsavich, global head, RNA medicine lead at Pfizer.
Access options
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Additional access options:
doi: https://doi.org/10.1038/d41573-022-00156-5
Jobs
留言 (0)